Seguir
Willy Hugo, PhD
Willy Hugo, PhD
UCLA School of Medicine
Dirección de correo verificada de mednet.ucla.edu
Título
Citado por
Citado por
Año
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
W Hugo, JM Zaretsky, L Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
29442016
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
29132016
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell Reports 19 (6), 1189-1201, 2017
15952017
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
11552017
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ...
Nature medicine 25 (3), 477, 2019
10732019
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
1041*2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5, 5712, 2014
6302014
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
6032015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ...
Cancer cell 27 (2), 240-256, 2015
3702015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ...
European Journal of Cancer 51 (18), 2792-2799, 2015
3282015
Regional Glutamine Deficiency in Tumours Promotes De-differentiation through Inhibition of Histone Demethylation
M Pan, MA Reid, XH Lowman, RP Kulkarni, TQ Tran, X Liu, Y Yang, ...
Nature cell biology 18 (10), 1090, 2016
3242016
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ...
Cancer discovery 4 (4), 423-433, 2014
2872014
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
250
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ...
Cancer discovery 4 (1), 69-79, 2014
1822014
Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation
C Song, M Piva, L Sun, A Hong, G Moriceau, X Kong, H Zhang, S Lomeli, ...
Cancer Discovery, CD-17-0401, 2017
1532017
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
A Lee, L Sun, A Mochizuki, J Reynoso, J Orpilla, F Chow, J Kienzler, ...
1012021
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ...
Cancer Discovery 8 (1), 74-93, 2018
1012018
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
E Pérez-Guijarro, HH Yang, RE Araya, R El Meskini, HT Michael, ...
Nature Medicine 26 (5), 781-791, 2020
892020
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
AA Marusiak, ZC Edwards, W Hugo, EW Trotter, MR Girotti, ...
Nature communications 5, 2014
842014
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
B Titz, A Lomova, A Le, W Hugo, X Kong, J Ten Hoeve, M Friedman, H Shi, ...
Cell Discovery 2, 16028, 2016
672016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20